Michelle Robertson
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
GERN Highlights Imetelstat at International Hematology Congresses. Geron Corporation announced that it will give oral presentations on its drug Imetelstat at international hematology congresses in Europe and Asia. The presentations are part of the company’s effort to advance Imetelstat’s clinical development and share results with the medical community. The news comes as the stock trades near its 52‑week low and around a $1.40 support level, with recent signals indicating a revenue‑price divergence.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Editas Medicine upgraded to Buy with $5 price target. Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.
Transaction History
| VSTM | ▲ Buy | Grant | 36,000 | $0 | 5/21/2026 | View on chart |
| GERN | ▲ Buy | Option Exercise | 27,500 | $0 | 2/18/2026 | View on chart |
| GERN | ▼ Sell | Open Market | 9,855 | $19K | 2/18/2026 | View on chart |
| VSTM | ▲ Buy | Grant | 8,333 | $0 | 5/22/2025 | View on chart |
| VSTM | ▲ Buy | Grant | 8,333 | $0 | 6/18/2024 | View on chart |
| EDIT | ▼ Sell | Open Market | 949 | $9K | 5/11/2023 | View on chart |
| EDIT | ▼ Sell | Open Market | 184 | $2K | 3/3/2023 | View on chart |
| EDIT | ▲ Buy | Grant | 31,500 | $0 | 3/2/2023 | View on chart |
| EDIT | ▼ Sell | Open Market | 4,287 | $41K | 2/13/2023 | View on chart |
| EDIT | ▼ Sell | Open Market | 1,752 | $14K | 1/10/2023 | View on chart |
| EDIT | ▼ Sell | Open Market | 193 | $2K | 12/5/2022 | View on chart |
| EDIT | ▼ Sell | Open Market | 192 | $3K | 9/6/2022 | View on chart |
| EDIT | ▼ Sell | Open Market | 1,527 | $18K | 6/3/2022 | View on chart |
| EDIT | ▼ Sell | Open Market | 767 | $13K | 3/3/2022 | View on chart |
| EDIT | ▲ Buy | Grant | 53,499 | $0 | 2/10/2022 | View on chart |
| EDIT | ▼ Sell | Open Market | 1,744 | $45K | 1/11/2022 | View on chart |
| EDIT | ▲ Buy | Grant | 4,471 | $0 | 12/22/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Verastem presents ovarian cancer data at IGCS, outlines pipeline
Verastem Oncology reported a late‑breaking oral presentation of its RAMP 201 low‑grade serous ovarian cancer molecular profiling and tumor biomarker analysis at the IGCS 2026 Annual Global Meeting. The company also highlighted the launch of its ovarian cancer therapy and progress on the KRAS G12D program during an H.C. Wainwright event. These updates reflect ongoing clinical development and investor communication around its oncology pipeline.
Verastem presents ovarian cancer data at IGCS, outlines pipeline. Verastem Oncology reported a late‑breaking oral presentation of its RAMP 201 low‑grade serous ovarian cancer molecular profiling and tumor biomarker analysis at the IGCS 2026 Annual Global Meeting. The company also highlighted the launch of its ovarian cancer therapy and progress on the KRAS G12D program during an H.C. Wainwright event. These updates reflect ongoing clinical development and investor communication around its oncology pipeline.